<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:45:00Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10170140" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10170140</identifier>
        <datestamp>2023-05-11</datestamp>
        <setSpec>tp</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id>
              <journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id>
              <journal-title-group>
                <journal-title>Translational Psychiatry</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2158-3188</issn>
              <publisher>
                <publisher-name>Nature Publishing Group UK</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10170140</article-id>
              <article-id pub-id-type="pmcid">PMC10170140</article-id>
              <article-id pub-id-type="pmc-uid">10170140</article-id>
              <article-id pub-id-type="pmid">37160885</article-id>
              <article-id pub-id-type="publisher-id">2451</article-id>
              <article-id pub-id-type="doi">10.1038/s41398-023-02451-0</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kopelman</surname>
                    <given-names>Jared</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Keller</surname>
                    <given-names>Timothy A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Panny</surname>
                    <given-names>Benjamin</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Griffo</surname>
                    <given-names>Angela</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Degutis</surname>
                    <given-names>Michelle</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Spotts</surname>
                    <given-names>Crystal</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cruz</surname>
                    <given-names>Nicolas</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bell</surname>
                    <given-names>Elizabeth</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Do-Nguyen</surname>
                    <given-names>Kevin</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wallace</surname>
                    <given-names>Meredith L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2715-6641</contrib-id>
                  <name>
                    <surname>Mathew</surname>
                    <given-names>Sanjay J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Howland</surname>
                    <given-names>Robert H.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7590-4325</contrib-id>
                  <name>
                    <surname>Price</surname>
                    <given-names>Rebecca B.</given-names>
                  </name>
                  <address>
                    <email>rebecca.price@stanfordalumni.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>University of California San Diego School of Medicine, </institution></institution-wrap>San Diego, CA USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.147455.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2097 0344</institution-id><institution>Carnegie Mellon University, </institution></institution-wrap>Pittsburgh, PA USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.21925.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9000</institution-id><institution>University of Pittsburgh School of Medicine, </institution></institution-wrap>Pittsburgh, PA USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.413890.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0420 5521</institution-id><institution>Baylor College of Medicine and Michael E. DeBakey VA Medical Center, </institution></institution-wrap>Houston, TX USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>9</day>
                <month>5</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>9</day>
                <month>5</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2023</year>
              </pub-date>
              <volume>13</volume>
              <elocation-id>159</elocation-id>
              <history>
                <date date-type="received">
                  <day>25</day>
                  <month>3</month>
                  <year>2023</year>
                </date>
                <date date-type="rev-recd">
                  <day>17</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>25</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© The Author(s) 2023</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the articleâs Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the articleâs Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <p id="Par1">Intravenous ketamine is posited to rapidly reverse depression by rapidly enhancing neuroplasticity. In human patients, we quantified gray matter microstructural changes on a rapid (24-h) timescale within key regions where neuroplasticity enhancements post-ketamine have been implicated in animal models. In this study, 98 unipolar depressed adults who failed at least one antidepressant medication were randomized 2:1 to a single infusion of intravenous ketamine (0.5âmg/kg) or vehicle (saline) and completed diffusion tensor imaging (DTI) assessments at pre-infusion baseline and 24-h post-infusion. DTI mean diffusivity (DTI-MD), a putative marker of microstructural neuroplasticity in gray matter, was calculated for 7 regions of interest (left and right BA10, amygdala, and hippocampus; and ventral Anterior Cingulate Cortex) and compared to clinical response measured with the Montgomery-Asberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptoms-Self-Report (QIDS-SR). Individual differences in DTI-MD change (greater decrease from baseline to 24-h post-infusion, indicative of more neuroplasticity enhancement) were associated with larger improvements in depression scores across several regions. In the left BA10 and left amygdala, these relationships were driven primarily by the ketamine group (groupâ*âDTI-MD interaction effects: <italic>p</italic>â=â0.016â0.082). In the right BA10, these associations generalized to both infusion arms (<italic>p</italic>â=â0.007). In the left and right hippocampus, on the MADRS only, interaction effects were observed in the opposite direction, such that DTI-MD change was inversely associated with depression change in the ketamine arm specifically (groupâ*âDTI-MD interaction effects: <italic>p</italic>â=â0.032â0.06). The acute effects of ketamine on depression may be mediated, in part, by acute changes in neuroplasticity quantifiable with DTI.</p>
              </abstract>
              <kwd-group kwd-group-type="npg-subject">
                <title>Subject terms</title>
                <kwd>Depression</kwd>
                <kwd>Hippocampus</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000025</institution-id>
                      <institution>U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01MH113857</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Price</surname>
                      <given-names>Rebecca B.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>Â© Springer Nature Limited 2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1" sec-type="introduction">
              <title>Introduction</title>
              <p id="Par2">Major depressive disorder is the leading cause of disability adjusted life years (DALYs) in the USA and represents an enormous public health burden [<xref ref-type="bibr" rid="CR1">1</xref>]. Deficits in neuroplasticity and corresponding deficits in the ability to respond adaptively to the environment are seen in both depressed human subjects and in rodent models of depression-like behavior, and therefore may be a core mechanism underlying the disorder [<xref ref-type="bibr" rid="CR2">2</xref>]. A diversity of structural and functional deficits in neuroplasticity underlie depression-like behavioral states seen in rodents following stress exposure (e.g., anhedonia-like behavior, tested via the sucrose preference test; anxiety-like behavior, indexed by the novelty-suppressed feeding test; and despair-like behavior, observed during the forced swim test) [<xref ref-type="bibr" rid="CR3">3</xref>]. These neuroplasticity deficits include decreased long-term potentiation and/or increased long-term depression, decreased synaptic protein expression, impaired BDNF and mTOR signaling, decreased synaptogenesis/atrophy of existing synapses, and decreased neurogenesis/atrophy of neurons, ultimately resulting in dysfunction of corticolimbic circuits and expression of maladaptive behavioral strategies [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>â<xref ref-type="bibr" rid="CR8">8</xref>]. Effective antidepressant therapies have been shown to reverse many of these deficits, further emphasizing the relevance of these studies to depression and providing some of the strongest evidence to date that impairments in neuroplasticity may be a core mechanism underlying depression [<xref ref-type="bibr" rid="CR9">9</xref>â<xref ref-type="bibr" rid="CR12">12</xref>].</p>
              <p id="Par3">While functional neuroplasticity cannot be directly tested in the living human brain, post-mortem studies of depression show reductions in markers of neuroplasticity, including reduced BDNF and decreased synapses and synapse-related gene expression [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Neuroimaging studies in depressed subjects reveal hypofunction and gray matter volume loss in key corticolimbic structures including the PFC and hippocampus, as well as decreased functional integration across these regions and their associated networks. These neural network alterations are hypothesized to result in deficits in flexible cognition and affective processing that manifest in depressed patients as rigid, maladaptive behavioral responses [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p>
              <p id="Par4">Recent evidence has shown that ketamine, a dissociative anesthetic, has rapid and robust antidepressant effects, including in treatment-resistant patients for whom other therapies have been ineffective [<xref ref-type="bibr" rid="CR17">17</xref>â<xref ref-type="bibr" rid="CR22">22</xref>]. These results have been widely replicated, but the exact mechanisms by which ketamine reduces depressive symptomology remain unknown. Results in rodent models indicate that a single dose of ketamine induces robust markers of neuroplasticity in depression-relevant brain regions, including increased BDNF release and the stimulation of mTOR signaling in the PFC [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. In addition, ketamine induces an increase in synapse number and function in the PFC, reversing the loss of specific synapses by stress, an effect that seems necessary for the persistence of its antidepressant-like behavioral effects [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. In humans, ketamine also alters neural response to emotional stimuli [<xref ref-type="bibr" rid="CR25">25</xref>] and EEG gamma power [<xref ref-type="bibr" rid="CR26">26</xref>â<xref ref-type="bibr" rid="CR29">29</xref>], a putative marker of activity-dependent plasticity.</p>
              <p id="Par5">To our knowledge, no one has specifically linked microstructural neuroplasticity induced by ketamineâakin to the synaptogenesis in the PFC observed in animal modelsâto its antidepressant effects in humans. While real-time neuroplasticity cannot be directly assessed in the intact human brain, recent advances in neuroimaging have provided evidence that structural remodeling of the human brain can be measured within hours of its occurrence. Several studies have used diffusion tensor imaging (DTI), an MRI-based framework, as an indirect marker of neuroplasticity [<xref ref-type="bibr" rid="CR30">30</xref>â<xref ref-type="bibr" rid="CR33">33</xref>]. Mean diffusivity (MD) within gray matter regions, an index derived from DTI, is a measure of water diffusion and therefore tissue density. The generation of new synapses, an important common final pathway of neuroplasticity, results in a decrease in MD, as these novel synapses restrict the flow of water within gray matter [<xref ref-type="bibr" rid="CR30">30</xref>]. Studies have shown decreases in MD within memory-related brain regions within 2âh of training tasks [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. This finding was replicated in rodents, and the decrease in DTI-MD was shown to correlate with traditional markers of cellular and molecular neuroplasticity, including increased number of synaptic vesicles, astrocyte activation, and increased expression of synaptic-related proteins, including BDNF [<xref ref-type="bibr" rid="CR30">30</xref>]. Collectively, these findings in animals and humans specifically tie acute DTI-MD changes to neuroplasticity processes including those involved in synaptogenesisâa prominent mechanism implicated in ketamineâs mechanism of antidepressant action [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p>
              <p id="Par6">In the current study, we measured DTI-MD in depression-relevant brain regions (BA10, amygdala, hippocampus, and ventral ACC) before and 24-h following the administration of IV ketamine (0.5âmg/kg) or saline vehicle in depressed human subjects, and related individual differences in these acute neuroplasticity markers to the degree of clinical response 24-h post-infusion. We hypothesized that individual differences in region-specific changes in DTI-MD would predict the response to treatment primarily in patients receiving ketamine, with larger clinical improvements following ketamine tracking with greater degrees of structural change, putatively reflecting neuroplasticity enhancement.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <p id="Par7">This study included secondary analyses of data generated from clinical trial NCT03237286. Study design and primary clinical outcomes have been detailed previously [<xref ref-type="bibr" rid="CR34">34</xref>]. In the full trial, 154 adult subjects (age 18â60) with moderate to severe depression [Montgomery-Asberg Depression Rating Scale (MADRS [<xref ref-type="bibr" rid="CR35">35</xref>]) score â¥25] and at least one adequate, failed trial of an FDA-approved antidepressant medication in the current depressive episode (assessed via Antidepressant Treatment Response Questionnaire; ATRQ [<xref ref-type="bibr" rid="CR36">36</xref>]), were enrolled and randomized to receive either ketamine or vehicle in a 2:1 ratio. An experienced, Masterâs-level clinical rater (CRS) administered the MADRS (the primary clinician-rated outcome used for the clinical trial) prior to, and 24âh post-infusion to assess overall depression severity and change following intervention. Similarly, patients self-reported depressive symptoms before and 24-h following ketamine using the Quick Inventory of Depressive Symptoms (QIDS-SR) [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], the primary self-report outcome. A subset of these subjects (31 vehicle, 67 ketamine) had usable DTI neuroimaging data collected prior to and 24-h post-infusion and are included in the current analyses. Subjects received either ketamine (0.5âmg/kg) or vehicle (50âml 0.9% NaCl) infused over 40-min, as done previously [<xref ref-type="bibr" rid="CR39">39</xref>â<xref ref-type="bibr" rid="CR41">41</xref>]<xref ref-type="fn" rid="Fn1">1</xref>. All infusions were administered by blinded, licensed nurses in a medical hospital setting with linked ACLS-certified team, blinded study physician (RHH) oversight, and safety/adverse event monitoring sustained for 4-h post-infusion. Current medications and doses were obtained from subjects via the community treatment form or patient interview with study staff. When there was a discrepancy between these two sources or missing information that could not be resolved via subject follow-up, collateral was obtained from the patientâs electronic medical record. Medication burden was calculated based on the Anti-Depressant Treatment History Form (ATHF) [<xref ref-type="bibr" rid="CR42">42</xref>â<xref ref-type="bibr" rid="CR44">44</xref>]. The study was performed at the University of Pittsburgh and approved by the Internal Review Board of the University of Pittsburgh. All participants provided informed consent prior to any study procedure. See Table <xref rid="Tab1" ref-type="table">1</xref> for descriptive patient characteristics.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical and demographic characteristics of the sample with usable DTI neuroimaging data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Full sample (<italic>n</italic>â=â98)</th><th colspan="2">Ketamine (<italic>n</italic>â=â67)</th><th colspan="2">Saline (<italic>n</italic>â=â31)</th></tr></thead><tbody><tr><td colspan="7">Race/ethnicity</td></tr><tr><td>âNon-Hispanic Caucasian, <italic>n</italic> (%)</td><td>72</td><td>73.5%</td><td>47</td><td>70.15%</td><td>25</td><td>80.65%</td></tr><tr><td>âHispanic/Latino, <italic>n</italic> (%)</td><td>6</td><td>6.2%</td><td>6</td><td>8.96%</td><td>0</td><td>0.00%</td></tr><tr><td>âAfrican American, <italic>n</italic> (%)</td><td>4</td><td>4.1%</td><td>2</td><td>2.99%</td><td>2</td><td>6.45%</td></tr><tr><td>âAsian, <italic>n</italic> (%)</td><td>8</td><td>8.2%</td><td>6</td><td>8.96%</td><td>2</td><td>6.45%</td></tr><tr><td>âMore than one race, <italic>n</italic> (%)</td><td>7</td><td>7.10%</td><td>5</td><td>7.46%</td><td>2</td><td>6.45%</td></tr><tr><td>âUnknown/incomplete info, <italic>n</italic> (%)</td><td>1</td><td>1.06</td><td>1</td><td>1.49%</td><td>0</td><td>0.00%</td></tr><tr><td colspan="7">Sex</td></tr><tr><td>âAssigned female sex at birth, <italic>n</italic> (%)</td><td>61</td><td>62.2%</td><td>40</td><td>59.70%</td><td>21</td><td>67.74%</td></tr><tr><td>âTaking psychotropic medication, <italic>n</italic> (%)</td><td>78</td><td>80%</td><td>56</td><td>83.58%</td><td>22</td><td>70.97%</td></tr><tr><td>âPre-infusion baseline QIDS total score (SD)</td><td>15.36</td><td>3.99</td><td>15.34</td><td>4.22</td><td>15.39</td><td>3.50</td></tr><tr><td>âPre-infusion baseline MADRS total score</td><td>32.81</td><td>5.39</td><td>32.84</td><td>5.52</td><td>32.74</td><td>5.20</td></tr></tbody></table><table-wrap-foot><p>No variables in the table above differed as a function of treatment group according to unpaired <italic>t</italic>-tests (for continuous variables) or Chi-squared tests (for categorical variables) (<italic>p</italic>â&gt;â0.15).</p></table-wrap-foot></table-wrap></p>
              <sec id="Sec3">
                <title>Neuroimaging acquisition</title>
                <p id="Par9">All neuroimaging data were acquired using a 3T Siemens Prisma and a Siemens 64-channel head coil at the University of Pittsburgh. Diffusion-weighted structural images were acquired using the multi-band sequences (version R016A) provided by the University of Minnesota Center for Magnetic Resonance Research (<ext-link ext-link-type="uri" xlink:href="https://www.cmrr.umn.edu/multi">https://www.cmrr.umn.edu/multi</ext-link> band/). Diffusion-weighted images were collected as oblique-axial scans aligned with the anterior commissureâposterior commissure (ACâPC) line at midline with the monopolar cmrr_mbep2d_diff sequence (<ext-link ext-link-type="uri" xlink:href="http://www.cmrr.umn.edu/multi">http://www.cmrr.umn.edu/multi</ext-link> band) in 72 slices (an ascending interleaved acquisition with 2.0-mm-thick slices and no inter-slice gap). The matrix was 104âÃâ104 and FOV was 208âmm, resulting in 2.0-mm isotropic voxels (TRâ=â2443âms, TEâ=â88.0âms, multi-band acceleration factorâ=â4, number of diffusion encoded directionsâ=â30, diffusion <italic>b</italic> valueâ=â1000âs/mm<sup>2</sup>, number of non-diffusion-encoded imagesâ=â4, bandwidthâ=â2004 Hz/pixel, partial Fourier factor of 7/8). The 30 diffusion encoding vectors were taken from a standard Siemens gradient table. Two sets of these images with opposite phase encoding directions (anteriorâ-&gt;âposterior and posteriorâ-&gt;âanterior) were collected for each participant in each scanning session (baseline and 24-h). A high-resolution structural scan was also acquired at the baseline scan session (axial MPRAGE: TRâ=â2400; TEâ=â2.22; 208 slices; flip angleâ=â8Â°; 0.8âmm isotropic voxels).</p>
              </sec>
              <sec id="Sec4">
                <title>Neuroimaging processing</title>
                <p id="Par10">Images were preprocessed in FSL v. 5.0 (<ext-link ext-link-type="uri" xlink:href="https://fsl.fmrib.ox.ac.uk/fsl/fslwiki">https://fsl.fmrib.ox.ac.uk/fsl/fslwiki</ext-link>) following a standard DTI pipeline [<xref ref-type="bibr" rid="CR33">33</xref>] that included the following steps: correction of geometric distortions (topup), motion (mcflirt), and eddy currents (eddy); linear co-registration of baseline and 24-h data (flirt); non-linear warping to MNI space (fsl_reg to âFMRIB58_FA_1mmâ template); and fitting a weighted-least squared diffusion tensor model (dtifit) to produce voxel-wise maps of mean diffusivity at each scan session. A DTI-MD change score (â-MDâ=âMD pre-infusionâââMD at 24âh) was then calculated for each of the following ROIs: left and right BA10, left and right amygdala, left and right hippocampus, and ventral anterior cingulate cortex (vACC; encompassing subgenual and perigenual ACC). These specific regions were selected for analysis based on a priori hypotheses about the role of these regions in both the antidepressant response to ketamine (which has particularly implicated hippocampus and medial PFC areas, including bilateral BA10 and vACC; see [<xref ref-type="bibr" rid="CR2">2</xref>]) and in depression pathophysiology at large, which additionally establishes a prominent role for the amygdala in depressed patientsâ altered patterns of affective processing (reviewed in [<xref ref-type="bibr" rid="CR2">2</xref>]). Anatomical masks for each ROI were constructed using the MNI atlas and applied to extract the MD score for each participant as an average of all voxels within each ROI. A higher â-MD score corresponds to lower mean diffusivity following the infusion, and putatively greater plasticity/synaptogenesis [<xref ref-type="bibr" rid="CR30">30</xref>]. A Winsorizing procedure was used to rescale extreme â-MD values prior to analysis, as described previously [<xref ref-type="bibr" rid="CR45">45</xref>].</p>
                <p id="Par11">All statistics were run using IBM SPSS Statistics (version 28.0.1.0). To test for the effect of group (ketamine vs. vehicle) on â depression scores and â-MD, two-tailed independent sample <italic>t</italic>-tests were performed. Multiple linear regression was performed to predict the improvement in depression (measured as change in MADRS and QIDS-SR scores) from â-MD and group (ketamine vs. vehicle), as well as their interactionâenabling formal assessment of any distinct relationships between neuroplasticity and clinical improvement that were evident in the ketamine vs. vehicle arms. Parallel, exploratory analyses of three additional outcome measures (measuring anxiety, positive affect, and dissociative side effects) are presented in the online Supplement.</p>
              </sec>
            </sec>
            <sec id="Sec5" sec-type="results">
              <title>Results</title>
              <sec id="Sec6">
                <title>Main effects of treatment group</title>
                <p id="Par12">In the full clinical trial sample, ketamine significantly improved MADRS (<italic>t</italic>(150)â=ââ4.55, <italic>p</italic>â&lt;â0.001) and QIDS (<italic>t</italic>(148)â=ââ2.60, <italic>p</italic>â=â0.010) scores 24-h post-infusion. In the subset of patients with DTI neuroimaging data, ketamine significantly improved MADRS scores 24-h post-infusion (<italic>t</italic>(96)â=ââ3.01, <italic>p</italic>â=â0.003), while there was no significant effect of ketamine on change in QIDS-SR score 24-h post-infusion in this subset of patients (<italic>t</italic>(95)â=ââ1.10, <italic>p</italic>â=â0.28). Ketamine had no significant main effect on either raw or Winsorized â-MD values in any of the regions investigated.</p>
              </sec>
              <sec id="Sec7">
                <title>Moderation of clinical outcomes by rapid change in MD</title>
                <p id="Par13">Linear regression was performed to predict the improvement in QIDS and MADRS from â-MD values, group (ketamine vs. vehicle), and their interaction. Results for all regions are shown in Table <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Interaction term (group * change in mean diffusivity) statistics and robustness of findings when utilizing clinician-administered (MADRS) vs. self-report (QIDS) outcomes and when including covariates in models.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Region</th><th>No covariate</th><th>Covarying TRD severity</th><th>Covarying medication burden</th><th>Covarying pre-MD</th></tr></thead><tbody><tr><td colspan="5">MADRS</td></tr><tr><td>L BA10</td><td><italic>âR</italic><sup>2</sup>â=â0.029; <italic>Î²</italic>â=â0.308; <italic>t</italic><sub>96</sub>â=â1.760; <italic>p</italic>â=â0.082</td><td><italic>âR</italic><sup>2</sup>â=â0.022; <italic>Î²</italic>â=â0.267; <italic>t</italic><sub>96</sub>â=â1.534; <italic>p</italic>â=â0.128</td><td><italic>âR</italic><sup>2</sup>â=â0.028; <italic>Î²</italic>â=â0.302; <italic>t</italic><sub>96</sub>â=â1.716; <italic>p</italic>â=â0.089</td><td><italic>âR</italic><sup>2</sup>â=â0.035; <italic>Î²</italic>â=â0.290; <italic>t</italic><sub>96</sub>â=â1.641; <italic>p</italic>â=â0.104</td></tr><tr><td>R BA10</td><td><italic>âR</italic><sup>2</sup>â=â0.000; <italic>Î²</italic>â=â0.019; <italic>t</italic><sub>96</sub>â=â0.109; <italic>p</italic>â=â0.913</td><td><italic>âR</italic><sup>2</sup>â=â0.002; <italic>Î²</italic>â=ââ0.083; <italic>t</italic><sub>96</sub>â=ââ0.474; <italic>p</italic>â=â0.637</td><td><italic>âR</italic><sup>2</sup>â=â0.000; <italic>Î²</italic>â=â0.013; <italic>t</italic><sub>96</sub>â=â0.078; <italic>p</italic>â=â0.938</td><td><italic>âR</italic><sup>2</sup>â=â0.001; <italic>Î²</italic>â=ââ0.043; <italic>t</italic><sub>96</sub>â=ââ0.250; <italic>p</italic>â=â0.803</td></tr><tr><td>L Amygdala</td><td><italic>âR</italic><sup>2</sup>â=â0.045; <italic>Î²</italic>â=â0.414; <italic>t</italic><sub>96</sub>â=â2.238; <italic>p</italic>â=â0.028</td><td><italic>âR</italic><sup>2</sup>â=â0.055; <italic>Î²</italic>â=â0.459; <italic>t</italic><sub>96</sub>â=â2.518; <italic>p</italic>â=â0.014</td><td><italic>âR</italic><sup>2</sup>â=â0.043; <italic>Î²</italic>â=â0.410; <italic>t</italic><sub>96</sub>â=â2.188; <italic>p</italic>â=â0.031</td><td><italic>âR</italic><sup>2</sup>â=â0.044; <italic>Î²</italic>â=â0.414; <italic>t</italic><sub>96</sub>â=â2.13; <italic>p</italic>â=â0.029</td></tr><tr><td>R Amygdala</td><td><italic>âR</italic><sup>2</sup>â=â0.001; <italic>Î²</italic>â=ââ0.046; <italic>t</italic><sub>96</sub>â=ââ0.255; <italic>p</italic>â=â0.799</td><td><italic>âR</italic><sup>2</sup>â=â0.000; <italic>Î²</italic>â=ââ0.028; <italic>t</italic><sub>96</sub>â=ââ0.158; <italic>p</italic>â=â0.874</td><td><italic>âR</italic><sup>2</sup>â=â0.001; <italic>Î²</italic>â=ââ0.049; <italic>t</italic><sub>96</sub>â=ââ0.270; <italic>p</italic>â=â0.788</td><td><italic>âR</italic><sup>2</sup>â=â0.001; <italic>Î²</italic>â=ââ0.048; <italic>t</italic><sub>96</sub>â=ââ0.266; <italic>p</italic>â=â0.791</td></tr><tr><td>L Hippocampus</td><td><italic>âR</italic><sup>2</sup>â=â0.044; <italic>Î²</italic>â=ââ0.337; <italic>t</italic><sub>96</sub>â=ââ2.178; <italic>p</italic>â=â0.032</td><td><italic>âR</italic><sup>2</sup>â=â0.048; <italic>Î²</italic>â=ââ0.351; <italic>t</italic><sub>96</sub>â=ââ2.315; <italic>p</italic>â=â0.023</td><td><italic>âR</italic><sup>2</sup>â=â0.044; <italic>Î²</italic>â=ââ0.338; <italic>t</italic><sub>96</sub>â=ââ2.175; <italic>p</italic>â=â0.032</td><td><italic>âR</italic><sup>2</sup>â=â0.045; <italic>Î²</italic>â=ââ0.343; <italic>t</italic><sub>96</sub>â=ââ2.202; <italic>p</italic>â=â0.030</td></tr><tr><td>R Hippocampus</td><td><italic>âR</italic><sup>2</sup>â=â0.033; <italic>Î²</italic>â=ââ0.303; <italic>t</italic><sub>96</sub>â=ââ1.902; <italic>p</italic>â=â0.060</td><td><italic>âR</italic><sup>2</sup>â=â0.035; <italic>Î²</italic>â=ââ0.310; <italic>t</italic><sub>96</sub>â=ââ1.986; <italic>p</italic>â=â0.050</td><td><italic>âR</italic><sup>2</sup>â=â0.034; <italic>Î²</italic>â=ââ0.308; <italic>t</italic><sub>96</sub>â=ââ1.923; <italic>p</italic>â=â0.058</td><td><italic>âR</italic><sup>2</sup>â=â0.033; <italic>Î²</italic>â=ââ0.304; <italic>t</italic><sub>96</sub>â=ââ1.897; <italic>p</italic>â=â0.061</td></tr><tr><td>vACC</td><td><italic>âR</italic><sup>2</sup>â=â0.001; <italic>Î²</italic>â=ââ0.043; <italic>t</italic><sub>96</sub>â=ââ0.254; <italic>p</italic>â=â0.800</td><td><italic>âR</italic><sup>2</sup>â=â0.000; <italic>Î²</italic>â=ââ0.032; <italic>t</italic><sub>96</sub>â=ââ0.193; <italic>p</italic>â=â0.847</td><td><italic>âR</italic><sup>2</sup>â=â0.001; <italic>Î²</italic>â=ââ0.042; <italic>t</italic><sub>96</sub>â=ââ0.246; <italic>p</italic>â=â0.806</td><td><italic>âR</italic><sup>2</sup>â=â0.001; <italic>Î²</italic>â=ââ0.055; <italic>t</italic><sub>96</sub>â=ââ0.322; <italic>p</italic>â=â0.748</td></tr><tr><td colspan="5">QIDS</td></tr><tr><td>L BA10</td><td><italic>âR</italic><sup>2</sup>â=â0.045; <italic>Î²</italic>â=â0.386; <italic>t</italic><sub>96</sub>â=â2.143; <italic>p</italic>â=â0.035</td><td><italic>âR</italic><sup>2</sup>â=â0.037; <italic>Î²</italic>â=â0.352; <italic>t</italic><sub>96</sub>â=â1.952; <italic>p</italic>â=â0.054</td><td><italic>âR</italic><sup>2</sup>â=â0.043; <italic>Î²</italic>â=â0.377; <italic>t</italic><sub>96</sub>â=â2.084; <italic>p</italic>â=â0.040</td><td><italic>âR</italic><sup>2</sup>â=â0.046; <italic>Î²</italic>â=â0.382; <italic>t</italic><sub>96</sub>â=â2.094; <italic>p</italic>â=â0.039</td></tr><tr><td>R BA10</td><td><italic>âR</italic><sup>2</sup>â=â0.016; <italic>Î²</italic>â=â0.238; <italic>t</italic><sub>96</sub>â=â1.305; <italic>p</italic>â=â0.195</td><td><italic>âR</italic><sup>2</sup>â=â0.007; <italic>Î²</italic>â=â0.160; <italic>t</italic><sub>96</sub>â=â0.855; <italic>p</italic>â=â0.395</td><td><italic>âR</italic><sup>2</sup>â=â0.016; <italic>Î²</italic>â=â0.233; <italic>t</italic><sub>96</sub>â=â1.276; <italic>p</italic>â=â0.205</td><td><italic>âR</italic><sup>2</sup>â=â0.010; <italic>Î²</italic>â=â0.212; <italic>t</italic><sub>96</sub>â=â1.144; <italic>p</italic>â=â0.256</td></tr><tr><td>L Amygdala</td><td><italic>âR</italic><sup>2</sup>â=â0.059; <italic>Î²</italic>â=â0.477; <italic>t</italic><sub>96</sub>â=â2.446; <italic>p</italic>â=â0.016</td><td><italic>âR</italic><sup>2</sup>â=â0.070; <italic>Î²</italic>â=â0.521; <italic>t</italic><sub>96</sub>â=â2.711; <italic>p</italic>â=â0.008</td><td><italic>âR</italic><sup>2</sup>â=â0.056; <italic>Î²</italic>â=â0.465; <italic>t</italic><sub>96</sub>â=â2.359; <italic>p</italic>â=â0.020</td><td><italic>âR</italic><sup>2</sup>â=â0.050; <italic>Î²</italic>â=â0.440; <italic>t</italic><sub>96</sub>â=â2.261; <italic>p</italic>â=â0.026</td></tr><tr><td>R Amygdala</td><td><italic>âR</italic><sup>2</sup>â=â0.001; <italic>Î²</italic>â=ââ0.063; <italic>t</italic><sub>96</sub>â=ââ0.333; <italic>p</italic>â=â0.740</td><td><italic>âR</italic><sup>2</sup>â=â0.001; <italic>Î²</italic>â=ââ0.047 <italic>t</italic><sub>96</sub>â=ââ0.254; <italic>p</italic>â=â0.800</td><td><italic>âR</italic><sup>2</sup>â=â0.001; <italic>Î²</italic>â=ââ0.068; <italic>t</italic><sub>96</sub>â=ââ0.360; <italic>p</italic>â=â0.719</td><td><italic>âR</italic><sup>2</sup>â=â0.002; <italic>Î²</italic>â=ââ0.072; <italic>t</italic><sub>96</sub>â=ââ0.392; <italic>p</italic>â=â0.696</td></tr><tr><td>L Hippocampus</td><td><italic>âR</italic><sup>2</sup>â=â0.001; <italic>Î²</italic>â=ââ0.061; <italic>t</italic><sub>96</sub>â=ââ0.353; <italic>p</italic>â=â0.725</td><td><italic>âR</italic><sup>2</sup>â=â0.002; <italic>Î²</italic>â=ââ0.065; <italic>t</italic><sub>96</sub>â=ââ0.383; <italic>p</italic>â=â0.702</td><td><italic>âR</italic><sup>2</sup>â=â0.001; <italic>Î²</italic>â=ââ0.060; <italic>t</italic><sub>96</sub>â=ââ0.351; <italic>p</italic>â=â0.727</td><td><italic>âR</italic><sup>2</sup>â=â0.002; <italic>Î²</italic>â=ââ0.070; <italic>t</italic><sub>96</sub>â=ââ0.410; <italic>p</italic>â=â0.683</td></tr><tr><td>R Hippocampus</td><td><italic>âR</italic><sup>2</sup>â=â0.000; <italic>Î²</italic>â=ââ0.011; <italic>t</italic><sub>96</sub>â=ââ0.063; <italic>p</italic>â=â0.950</td><td><italic>âR</italic><sup>2</sup>â=â0.000; <italic>Î²</italic>â=ââ0.010; <italic>t</italic><sub>96</sub>â=ââ0.059; <italic>p</italic>â=â0.953</td><td><italic>âR</italic><sup>2</sup>â=â0.000; <italic>Î²</italic>â=ââ0.017; <italic>t</italic><sub>96</sub>â=ââ0.096; <italic>p</italic>â=â0.924</td><td><italic>âR</italic><sup>2</sup>â=â0.000; <italic>Î²</italic>â=ââ0.007; <italic>t</italic><sub>96</sub>â=â0.042; <italic>p</italic>â=â0.967</td></tr><tr><td>vACC</td><td><italic>âR</italic><sup>2</sup>â=â0.005; <italic>Î²</italic>â=â0.124; <italic>t</italic><sub>96</sub>â=â0.695; <italic>p</italic>â=â0.489</td><td><italic>âR</italic><sup>2</sup>â=â0.006; <italic>Î²</italic>â=â0.140; <italic>t</italic><sub>96</sub>â=â0.793; <italic>p</italic>â=â0.430</td><td><italic>âR</italic><sup>2</sup>â=â0.005; <italic>Î²</italic>â=â0.128; <italic>t</italic><sub>96</sub>â=â0.713; <italic>p</italic>â=â0.478</td><td><italic>âR</italic><sup>2</sup>â=â0.005; <italic>Î²</italic>â=â0.118; <italic>t</italic><sub>96</sub>â=â0.654; <italic>p</italic>â=â0.515</td></tr></tbody></table><table-wrap-foot><p>The values provided for <italic>âR</italic><sup>2</sup><italic>, Î²</italic>, <italic>t</italic>, and <italic>p</italic> in each column above all uniformly correspond to the addition of the groupâ*â<italic>â</italic>MD interaction term (for the specified region) into regression models which also contain main effects of group and <italic>â</italic>MD in predicting % improvement in the MADRS (top half of table) and QIDS (bottom half of table). The âNo Covariateâ column reflects the statistics for primary models, as reported in âResultsâ section text; the additional 3 columns to the right reflect the impact on the interaction term statistics when also including each specified variable as a covariate in models.</p></table-wrap-foot></table-wrap></p>
                <sec id="Sec8">
                  <title>L BA10</title>
                  <p id="Par14">For QIDS scores, there was a significant â-MDâ*âgroup interaction effect, such that decreased MD scores (i.e., putative neuroplasticity increase) predicted greater improvement in QIDS scores in the ketamine group specifically (<italic>Î²</italic>â=â0.386, <italic>t</italic>(96)â=â2.143, <italic>p</italic>â=â0.035; Fig. <xref rid="Fig1" ref-type="fig">1A</xref>). For MADRS scores, there was a significant main effect of group (<italic>Î²</italic>â=â0.314, <italic>t</italic>(96)â=â3.207, <italic>p</italic>â=â0.002) and a trend for a â-MDâ*âgroup interaction effect (<italic>Î²</italic>â=â0.308, <italic>t</italic>(96)â=â1.760, <italic>p</italic>â=â0.082; Fig. <xref rid="Fig1" ref-type="fig">1B</xref>). Greater improvement in MADRS scores was associated with a reduction in MD, and this relationship was particularly evident in the ketamine group.<fig id="Fig1"><label>Fig. 1</label><caption><title>Associations between change in depression and change in mean diffusivity as a function of treatment.</title><p>Within-group correlations between change in QIDS-SR (<bold>A</bold>, <bold>C</bold>, <bold>E</bold>) or MADRS (<bold>B</bold>, <bold>D</bold>, <bold>F</bold>) scores and the change in mean diffusivity for select brain regions. Post hoc Pearson <italic>r</italic> and <italic>p</italic> values shown separately for the vehicle (<italic>n</italic>â=â31) and ketamine (<italic>n</italic>â=â67) groups; see main text and Table <xref rid="Tab2" ref-type="table">2</xref> for full omnibus regression statistics. A positive change in depression score indicates an improvement in depression on that scale, and a positive change in MD indicates decreased diffusion in that region (interpreted as increased plasticity).</p></caption><graphic xlink:href="41398_2023_2451_Fig1_HTML" id="d32e2103"/></fig></p>
                </sec>
                <sec id="Sec9">
                  <title>R BA10</title>
                  <p id="Par15">There was a significant main effect of â-MD on QIDS (â-MD: <italic>Î²</italic>â=â0.275, <italic>t</italic>(96)â=â2.771, <italic>p</italic>â=â0.007; Fig. <xref rid="Fig1" ref-type="fig">1C</xref>) and a significant main effect of both â-MD and group on MADRS scores (â-MD: <italic>Î²</italic>â=â0.196, <italic>t</italic>(96)â=â2.019, <italic>p</italic>â=â0.046; group: <italic>Î²</italic>â=â0.268, <italic>t</italic>(96)â=â2.763 <italic>p</italic>â=â0.007; Fig. <xref rid="Fig1" ref-type="fig">1D</xref>), such that reduced MD predicted greater improvement in depression score (independent of group). There was no significant â-MDâ*âgroup interaction effect in this region for either QIDS or MADRS (<italic>p</italic>ââ¥â0.195).</p>
                </sec>
                <sec id="Sec10">
                  <title>L amygdala</title>
                  <p id="Par16">There was a significant â-MDâ*âgroup interaction effect on both QIDS (<italic>Î²</italic>â=â0.477, <italic>t</italic>(96)â=â2.446, <italic>p</italic>â=â0.016; Fig. <xref rid="Fig1" ref-type="fig">1E</xref>) and MADRS (<italic>Î²</italic>â=â0.414, <italic>t</italic>(96)â=â2.238, <italic>p</italic>â=â0.028; Fig. <xref rid="Fig1" ref-type="fig">1F</xref>) such that decreases in MD predicted greater improvement in depression in the ketamine group specifically.</p>
                </sec>
                <sec id="Sec11">
                  <title>L hippocampus</title>
                  <p id="Par17">For the MADRS only, there was a significant â-MDâ*âgroup interaction effect (<italic>Î²</italic>â=ââ0.337, <italic>t</italic>(96)â=ââ2.178, <italic>p</italic>â=â0.032; Fig. <xref rid="Fig2" ref-type="fig">2A</xref>). The directionality of these results is opposite to those in left BA10 and left amygdala above, such that increased MD predicted improved MADRS score in the ketamine group. There were no significant main or interaction effects predicting improvement in QIDS score (<italic>p</italic>â&gt;â0.05).<fig id="Fig2"><label>Fig. 2</label><caption><title>Associations between change in depression and change in hippocampal mean diffusivity as a function of treatment.</title><p>Within-group correlations between change in MADRS score and the change in mean diffusivity for left (<bold>A</bold>) and right (<bold>B</bold>) hippocampus. Post hoc Pearson <italic>r</italic> and <italic>p</italic> values shown separately for the vehicle (<italic>n</italic>â=â31) and ketamine (<italic>n</italic>â=â67) groups; see main text and Table <xref rid="Tab2" ref-type="table">2</xref> for full omnibus regression statistics. A positive change in depression score indicates an improvement in depression on the MADRS, and a positive change in MD indicates decreased diffusion in that region (interpreted as increased plasticity).</p></caption><graphic xlink:href="41398_2023_2451_Fig2_HTML" id="d32e2230"/></fig></p>
                </sec>
                <sec id="Sec12">
                  <title>R hippocampus</title>
                  <p id="Par18">For the MADRS only, there were significant main effects of group (<italic>Î²</italic>â=â0.343, <italic>t</italic>(96)â=â3.420, <italic>p</italic>â=â0.001) and a trend-level â-MDâ*âgroup interaction in right hippocampus (<italic>Î²</italic>â=ââ0.303, <italic>t</italic>(96)â=ââ1.902, <italic>p</italic>â=â0.060; Fig. <xref rid="Fig2" ref-type="fig">2B</xref>). Like in the left hippocampus, increased MD in the right hippocampus predicted improved MADRS score following ketamine. There were no significant main or interaction effects predicting improvement in QIDS score (<italic>p</italic>â&gt;â0.05).</p>
                </sec>
                <sec id="Sec13">
                  <title>Other regions examined and sensitivity analyses</title>
                  <p id="Par19">There were no significant main or interaction effects in the right amygdala or the vACC.</p>
                  <p id="Par20">Sensitivity analyses were performed to assess robustness of interaction effect findings when including the following covariates: baseline DTI-MD score, severity of treatment resistance [moderate (&lt;3 failed adequate trials) vs. severe], and use of concurrent psychotropic medications (see Table <xref rid="Tab2" ref-type="table">2</xref>). Inclusion of each covariate into our statistical models had minimal impact on the pattern and statistical significance of the findings described above.</p>
                </sec>
              </sec>
            </sec>
            <sec id="Sec14" sec-type="discussion">
              <title>Discussion</title>
              <p id="Par21">In the present study, we found an association between change in DTI-MD (â-MD), a putative marker of neuroplasticity, and treatment response to ketamine in a sample of patients with depression. Reductions in MD scores in left BA10 and left amygdala, representing putative increased plasticity in these regions, predicted greater improvement in depression scores specifically in patients receiving ketamine. In right BA10, decreased MD scores predicted greater improvement in depression scores, independent of group (as reflected in the lack of a significant groupâ*ââ-MD interaction effect). In both right and left hippocampus, the results were paradoxically in the opposite direction, with higher â-MD scores predicting greater improvement in clinician-rated depression scores in subjects receiving ketamine. However, there was no similar interaction between â-MD and group in predicting self-reported depression scores in either left or right hippocampus. Lastly, we found no significant effect of â-MD on depression scores in vACC or right amygdala. These findings were not appreciably changed in sensitivity analyses that included covariates in the statistical models, including concomitant psychiatric medication burden, level of treatment resistance, and baseline DTI-MD values (Table <xref rid="Tab2" ref-type="table">2</xref>).</p>
              <p id="Par22">To our knowledge, this is the first placebo-controlled human study to investigate the association between a structural marker of acute neuroplasticity in depression-relevant brain regions and treatment response to ketamine, providing a first attempt to translate animal neuroscience findings, which have widely implicated synaptogenic mechanisms of action, back to the clinic. The regions in which increased plasticity predicted change in depression scores are right and left BA10 and left amygdala. Activity in these regions has been shown to be altered in depressed subjects, with studies of BA10 (and nearby related PFC regions) showing hyperactivation to reward-related cues and hypoactivation to negative affective cues (e.g., negatively valanced faces) in depressed subjects relative to controls [<xref ref-type="bibr" rid="CR46">46</xref>]. Furthermore, a large body of literature in depressed subjects shows hyperactivation of the amygdala in response to negative affective cues and hypoactivation in response to positive affective cues (e.g., positively valanced faces) relative to controls [<xref ref-type="bibr" rid="CR47">47</xref>]. Antidepressants may also change activity in these regions, with a meta-analysis showing that the neural biases in emotional processing in depressed subjects in the PFC and amygdala were normalized following the administration of an SSRI [<xref ref-type="bibr" rid="CR48">48</xref>]. Some more recent evidence indicates that this may be true for treatment with ketamine as well, with decreased amygdala activity in response to emotionally salient stimuli being perhaps the most well-replicated finding in the ketamine neuroimaging literature [<xref ref-type="bibr" rid="CR49">49</xref>â<xref ref-type="bibr" rid="CR52">52</xref>]. Many previous neuroimaging studies of response to ketamine have also shown changes in functional connectivity across brain networks, and while this literature is expansive and varied, studies have consistently implicated functional connectivity involving BA10 and related PFC regions and the amygdala in the antidepressant response to ketamine [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR53">53</xref>â<xref ref-type="bibr" rid="CR56">56</xref>]. Interestingly, the laterality of regions involved in ketamine response in human neuroimaging research varies from study-to-study, with the exception of the left amygdala, which, as in our current study, is consistently implicated more commonly than the right amygdala [<xref ref-type="bibr" rid="CR50">50</xref>].</p>
              <p id="Par23">The structural mechanisms that underlie the functional changes in BA10 and left amygdala described above are unknown, but likely involve remodeling at the circuit, cellular, and/or synaptic level. This type of remodeling alters brain microstructure, leading to a change in the diffusion properties of water within this region (i.e., diffusion is restricted), resulting in a decrease in MD that reflects increased neuroplasticity [<xref ref-type="bibr" rid="CR30">30</xref>â<xref ref-type="bibr" rid="CR32">32</xref>]. The changes we observed in BA10 and left amygdala following ketamine administration could represent a structural correlate of the antidepressant behavioral effect of the drug. Ketamine rapidly alters neural and behavioral responses to incoming stimuli, with changes in how brain regions respond to emotional stimuli and accompanying changes in behavioral output [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. One way by which this could happen is the rearrangement of multi-synaptic connections between sensory input and behavioral output, reflected in this study as a decrease in MD. The amygdala in particular plays an important role in responding to emotional stimuli and regulating behavioral output. Structural plasticity in this region might thus be readily leveraged to reduce the salience of negative stimuli and increase the salience of positive emotional stimuli. Through further testing of this hypothesis, the molecular effects of ketamine might be traced to its neural and behavioral effects in human patients.</p>
              <p id="Par24">While in left BA10 there was a significant â-MDâÃâgroup interaction effect, there was no similar interaction effect in the right BA10. This could indicate that plasticity in this region may play a larger role in the non-specific antidepressant effects that are common between the ketamine and placebo control groups, such as those associated with the infusion/research protocol, including the formation of therapeutic relationships, being in a therapeutic environment, positive feelings of helping others by contributing to research, and expectation of improvement.</p>
              <p id="Par25">In contrast to the results seen in BA10 and left amygdala, which conformed to expectations based on the animal literature, in both the left and right hippocampus there was a significant effect in the opposite direction, with increased MD being associated with improved clinician-rated depression scores in the ketamine group. Unlike the majority of other findings we report, which were largely robust across both clinician- and self-rated depression symptoms (e.g., Fig. <xref rid="Fig1" ref-type="fig">1</xref> and Table <xref rid="Tab2" ref-type="table">2</xref>), this pattern did not generalize to the QIDS, and may therefore be less reliable. While a decrease in MD is assumed to represent increased plasticity, with some mechanistic data to support this [<xref ref-type="bibr" rid="CR30">30</xref>], the interpretation of increased MD is less straightforward. Increased MD could represent an inverse mechanism of the decrease in MD, i.e., increased MDâ=âdecreased plasticity. If this is the case, it may be that ketamine causes selective pruning of hippocampal synapses (e.g., those associated with maladaptive behavioral responses). However, it seems unlikely that an overall decrease in plasticity of the hippocampus would be associated with improved depression scores following ketamine, especially in a sample of depressed subjects where low levels of hippocampal plasticity and structural integrity are posited to occur at baseline. Other interpretations are potentially more likely and are not mutually exclusive. Increased MD has been associated with specific behavioral states, including higher empathizing and cooperativeness [<xref ref-type="bibr" rid="CR57">57</xref>], which might be more likely to occur in patients with more improved depression scores. It has also previously been reported that MD increases in response to increases in cerebral blood flow (CBF) [<xref ref-type="bibr" rid="CR58">58</xref>â<xref ref-type="bibr" rid="CR60">60</xref>]. There is some evidence that improvement in particular symptom domains, namely anhedonia, is positively correlated with regional glucose metabolic rates, and we cannot rule out CBF increases being similarly associated with antidepressant response as well as increased MD. Other causes of increased MD, such as changes in dopamine or iron content of tissue, atrophy, or inflammation are possible, but less likely to be occurring in the hippocampus 24-h following the administration of ketamine [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR61">61</xref>].</p>
              <p id="Par26">Finally, we did not observe any relationships between clinical outcomes and â-MD in two other regions included in analyses: right amygdala and vACC. Relative to the other regions under examination, the specific neural processes captured via DTI-MD within these two regions may play a less foundational role in ketamineâs rapid antidepressant effects; although we cannot rule out other possible explanations, such as measurement error, insufficient sample size, and other contributors to Type II error.</p>
              <p id="Par27">Our data have clinical implications for the use of ketamine for depression. The plasticity induced by ketamine seems to persist, at least out to 24-h post-infusion, and potentially well beyond this. We can take advantage of this period of increased plasticity to augment the antidepressant effects of ketamine by combining it with other therapies, such as cognitive training. Indeed, in the primary outcome for this clinical trial, we previously reported that Automated Self-Association Trainingâa novel, low-cost, brief, computer-based interventionâextended the rapid antidepressant effect of a single ketamine infusion for at least 30 days [<xref ref-type="bibr" rid="CR34">34</xref>]. In addition to this potential for combinatorial, synergistic treatments, this study also points to the potential importance of the environment following treatment. If the brain is in a plastic state following ketamine, then the potential impact of the environment over the next 24+âh could be outsized, with a therapeutic environment potentially strengthening the effects of ketamine and a stressful environment potentially weakening them.</p>
              <p id="Par28">There are some limitations to the current study. Our measure of acute neuroplasticity, â-MD, is by necessity an indirect measure. While the previous studies using this metric as a measure of acute plasticity were investigating changes in hippocampal MD following learning, we are using it as a proxy for neuroplasticity in the context of treatment response for psychiatric disorders. Other factors that affect the diffusion of water, such as inflammation, could serve as confounds for our interpretation. The study was also limited by sample size, with 31 vehicle and 67 ketamine subjects, which is a subset of the whole clinical trial, and was likely underpowered to detect some interaction effects suggested by visual plots (Fig. <xref rid="Fig1" ref-type="fig">1</xref>), as well as a main effect of ketamine on QIDS scores, an effect that was present in the whole sample. The difference in sample sizes also makes us better powered to find significant post hoc correlations between changes in depression score and â-MD in specific regions in the ketamine group relative to the saline group. In an effort to balance between Type I and Type II error risk, we selected a constrained set of 7 regions a priori and did not adjust for multiple comparisons within this confined set. Our study also did not include individuals without depression, precluding the ability to assess for baseline group differences in DTI-MD as well as normalization of any such differences following ketamine. Changes in MD in several regions significantly predicted improvement in depression scores, however the effect sizes were relatively small, with <italic>R</italic><sup>2</sup> values between 0.05 and 0.18. Lastly, there was no main effect of ketamine on â-MD, as we might predict if it were the sole mediator of treatment response, indicating that numerous other factors are likely involved in the antidepressant effects of ketamine among human patients. Such factors could include additional neuroplasticity mechanisms, such as the impact of ketamine on white matter microstructure and tractography [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>] which was not assessed in the current study due to scanner sequence timing constraints and lack of a priori hypotheses regarding white matter effects; as well as a wide range of factors beyond neuroplasticity per se.</p>
            </sec>
            <sec id="Sec15" sec-type="conclusion">
              <title>Conclusion</title>
              <p id="Par29">In the past two decades, ketamine has emerged as one of the most promising pharmacological treatments for depression since selective serotonin re-uptake inhibitors (SSRIs) became available. While the exact mechanism is unknown, it has been hypothesized that ketamineâs antidepressant effects are at least in part mediated by increases in neuroplasticity broadly, and by synaptogenic actions specifically. We found that a proxy for structural neuroplasticity was associated with treatment response to ketamine in a subset of the depression-relevant brain regions we examined. These results have important implications for the development of synergistic therapies and for understanding the neurobiological mechanisms by which ketamine exerts rapid antidepressant actions in depressed patients.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary information</title>
              <sec id="Sec16">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="41398_2023_2451_MOESM1_ESM.docx">
                      <caption>
                        <p>Online Supplement</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn id="Fn1">
                <label>1</label>
                <p id="Par8"><italic>N</italic>â=â28 patients were enrolled prior to adding the DTI sequence to the MRI protocol; <italic>N</italic>â=â23 had unusable DTI data due to a scanner acquisition error at one or more timepoints; <italic>N</italic>â=â3 did not complete DTI sequence due to scanner time constraints; <italic>N</italic>â=â2 patients did not return to complete 24-h MRI scan.</p>
              </fn>
              <fn>
                <p><bold>Publisherâs note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <sec>
              <title>Supplementary information</title>
              <p>The online version contains supplementary material available at 10.1038/s41398-023-02451-0.</p>
            </sec>
            <ack>
              <title>Acknowledgements</title>
              <p>Supported by National Institute of Mental Health Biobehavioral Research Awards for Innovative New Scientists (BRAINS) R01 grant R01MH113857 (RBP) and by the Clinical and Translational Sciences Institute at the University of Pittsburgh (UL1-TR-001857). We are deeply grateful to the study participants for their time and dedicated collaboration in this work. We also gratefully acknowledge Chadi Abdallah, MD, PhD, Satish Iyengar, PhD, and Lisa Parker, PhD for their assistance with this work.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>TAK, MLW, SJM, and RBP contributed to the concept and design of the study. BP, AG, MD, CS, NC, KD-N, EB, RHH, and RBP contributed to the acquisition of the data. JK and RBP analyzed the data. JK drafted the manuscript and all authors provided substantive revisions.</p>
            </notes>
            <notes id="FPar1" notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par30">RBP is the named inventor on a University of Pittsburgh-owned patent filing related to a novel combination intervention tested in this clinical trial. SJM is supported through the use of facilities and resources at the Michael E. DeBakey VA Medical Center, Houston, Texas, and receives support from The Menninger Clinic. SJM has served as a consultant to Alkermes, Allergan, Axsome Therapeutics, BioXcel Therapeutics, Clexio Biosciences, Eleusis, EMA Wellness, Engrail Therapeutics, Greenwich Biosciences, Intra-Cellular Therapies, Janssen, Levo Therapeutics, Neurocrine, Perception Neuroscience, Praxis Precision Medicines, Relmada Therapeutics, Sage Therapeutics, Seelos Therapeutics, Sunovion, and Signant Health. He has received research support from Biohaven Pharmaceuticals, Merck, Neurocrine, Sage Therapeutics, and VistaGen Therapeutics. All other authors report no financial conflicts of interest to disclose.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <collab>GBD 2019 Mental Disorders Collaborators.</collab>
                  </person-group>
                  <article-title>Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019</article-title>
                  <source>Lancet Psychiatry</source>
                  <year>2022</year>
                  <volume>9</volume>
                  <fpage>137</fpage>
                  <lpage>50</lpage>
                  <pub-id pub-id-type="doi">10.1016/S2215-0366(21)00395-3</pub-id>
                  <pub-id pub-id-type="pmid">35026139</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Price</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Duman</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model</article-title>
                  <source>Mol Psychiatry</source>
                  <year>2020</year>
                  <volume>25</volume>
                  <fpage>530</fpage>
                  <lpage>43.</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41380-019-0615-x</pub-id>
                  <?supplied-pmid 31801966?>
                  <pub-id pub-id-type="pmid">31801966</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Timberlake</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Prall</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Dwivedi</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>The recent progress in animal models of depression</article-title>
                  <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
                  <year>2017</year>
                  <volume>77</volume>
                  <fpage>99</fpage>
                  <lpage>109</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.04.008</pub-id>
                  <?supplied-pmid 28396255?>
                  <pub-id pub-id-type="pmid">28396255</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>From serotonin to neuroplasticity: evolvement of theories for major depressive disorder</article-title>
                  <source>Front Cell Neurosci</source>
                  <year>2017</year>
                  <volume>11</volume>
                  <fpage>305</fpage>
                  <pub-id pub-id-type="doi">10.3389/fncel.2017.00305</pub-id>
                  <?supplied-pmid 29033793?>
                  <pub-id pub-id-type="pmid">29033793</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>CastrÃ©n</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Monteggia</surname>
                      <given-names>LM</given-names>
                    </name>
                  </person-group>
                  <article-title>Brain-derived neurotrophic factor signaling in depression and antidepressant action</article-title>
                  <source>Biol Psychiatry</source>
                  <year>2021</year>
                  <volume>90</volume>
                  <fpage>128</fpage>
                  <lpage>36.</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.biopsych.2021.05.008</pub-id>
                  <?supplied-pmid 34053675?>
                  <pub-id pub-id-type="pmid">34053675</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>De Gregorio</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Aguilar-Valles</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Preller</surname>
                      <given-names>KH</given-names>
                    </name>
                    <name>
                      <surname>Heifets</surname>
                      <given-names>BD</given-names>
                    </name>
                    <name>
                      <surname>Hibicke</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Mitchell</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Hallucinogens in mental health: preclinical and clinical studies on lsd, psilocybin, mdma, and ketamine</article-title>
                  <source>J Neurosci</source>
                  <year>2021</year>
                  <volume>41</volume>
                  <fpage>891</fpage>
                  <lpage>900</lpage>
                  <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1659-20.2020</pub-id>
                  <?supplied-pmid 33257322?>
                  <pub-id pub-id-type="pmid">33257322</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Aleksandrova</surname>
                      <given-names>LR</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>YT</given-names>
                    </name>
                    <name>
                      <surname>Phillips</surname>
                      <given-names>AG</given-names>
                    </name>
                  </person-group>
                  <article-title>Evaluation of the wistar-kyoto rat model of depression and the role of synaptic plasticity in depression and antidepressant response</article-title>
                  <source>Neurosci Biobehav Rev</source>
                  <year>2019</year>
                  <volume>105</volume>
                  <fpage>1</fpage>
                  <lpage>23</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neubiorev.2019.07.007</pub-id>
                  <?supplied-pmid 31336112?>
                  <pub-id pub-id-type="pmid">31336112</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Duman</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Aghajanian</surname>
                      <given-names>GK</given-names>
                    </name>
                    <name>
                      <surname>Sanacora</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Krystal</surname>
                      <given-names>JH</given-names>
                    </name>
                  </person-group>
                  <article-title>Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants</article-title>
                  <source>Nat Med</source>
                  <year>2016</year>
                  <volume>22</volume>
                  <fpage>238</fpage>
                  <lpage>49</lpage>
                  <pub-id pub-id-type="doi">10.1038/nm.4050</pub-id>
                  <?supplied-pmid 26937618?>
                  <pub-id pub-id-type="pmid">26937618</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Malberg</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Eisch</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Nestler</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Duman</surname>
                      <given-names>RS</given-names>
                    </name>
                  </person-group>
                  <article-title>Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus</article-title>
                  <source>J Neurosci</source>
                  <year>2000</year>
                  <volume>20</volume>
                  <fpage>9104</fpage>
                  <lpage>10</lpage>
                  <pub-id pub-id-type="doi">10.1523/JNEUROSCI.20-24-09104.2000</pub-id>
                  <?supplied-pmid 11124987?>
                  <pub-id pub-id-type="pmid">11124987</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>CastrÃ©n</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <article-title>Is mood chemistry?</article-title>
                  <source>Nat Rev Neurosci</source>
                  <year>2005</year>
                  <volume>6</volume>
                  <fpage>241</fpage>
                  <lpage>46</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrn1629</pub-id>
                  <?supplied-pmid 15738959?>
                  <pub-id pub-id-type="pmid">15738959</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Santarelli</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Saxe</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gross</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Surget</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Battaglia</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Dulawa</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants</article-title>
                  <source>Science.</source>
                  <year>2003</year>
                  <volume>301</volume>
                  <fpage>805</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.1126/science.1083328</pub-id>
                  <?supplied-pmid 12907793?>
                  <pub-id pub-id-type="pmid">12907793</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moda-Sava</surname>
                      <given-names>RN</given-names>
                    </name>
                    <name>
                      <surname>Murdock</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Parekh</surname>
                      <given-names>PK</given-names>
                    </name>
                    <name>
                      <surname>Fetcho</surname>
                      <given-names>RN</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>BS</given-names>
                    </name>
                    <name>
                      <surname>Huynh</surname>
                      <given-names>TN</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation</article-title>
                  <source>Science.</source>
                  <year>2019</year>
                  <volume>364</volume>
                  <fpage>eaat8078</fpage>
                  <pub-id pub-id-type="doi">10.1126/science.aat8078</pub-id>
                  <?supplied-pmid 30975859?>
                  <pub-id pub-id-type="pmid">30975859</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kang</surname>
                      <given-names>HJ</given-names>
                    </name>
                    <name>
                      <surname>Voleti</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Hajszan</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Rajkowska</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Stockmeier</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Licznerski</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Decreased expression of synapse-related genes and loss of synapses in major depressive disorder</article-title>
                  <source>Nat Med</source>
                  <year>2012</year>
                  <volume>18</volume>
                  <fpage>1413</fpage>
                  <lpage>17</lpage>
                  <pub-id pub-id-type="doi">10.1038/nm.2886</pub-id>
                  <?supplied-pmid 22885997?>
                  <pub-id pub-id-type="pmid">22885997</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sen</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Duman</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Sanacora</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications</article-title>
                  <source>Biol Psychiatry</source>
                  <year>2008</year>
                  <volume>64</volume>
                  <fpage>527</fpage>
                  <lpage>32</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.biopsych.2008.05.005</pub-id>
                  <?supplied-pmid 18571629?>
                  <pub-id pub-id-type="pmid">18571629</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Disner</surname>
                      <given-names>SG</given-names>
                    </name>
                    <name>
                      <surname>Beevers</surname>
                      <given-names>CG</given-names>
                    </name>
                    <name>
                      <surname>Haigh</surname>
                      <given-names>EAP</given-names>
                    </name>
                    <name>
                      <surname>Beck</surname>
                      <given-names>AT</given-names>
                    </name>
                  </person-group>
                  <article-title>Neural mechanisms of the cognitive model of depression</article-title>
                  <source>Nat Rev Neurosci</source>
                  <year>2011</year>
                  <volume>12</volume>
                  <fpage>467</fpage>
                  <lpage>77</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrn3027</pub-id>
                  <?supplied-pmid 21731066?>
                  <pub-id pub-id-type="pmid">21731066</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Siegle</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Thompson</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Carter</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Steinhauer</surname>
                      <given-names>SR</given-names>
                    </name>
                    <name>
                      <surname>Thase</surname>
                      <given-names>ME</given-names>
                    </name>
                  </person-group>
                  <article-title>Increased amygdala and decreased dorsolateral prefrontal bold responses in unipolar depression: related and independent features</article-title>
                  <source>Biol Psychiatry</source>
                  <year>2007</year>
                  <volume>61</volume>
                  <fpage>198</fpage>
                  <lpage>209</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.biopsych.2006.05.048</pub-id>
                  <?supplied-pmid 17027931?>
                  <pub-id pub-id-type="pmid">17027931</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Abdallah</surname>
                      <given-names>CG</given-names>
                    </name>
                    <name>
                      <surname>Sanacora</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Duman</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Krystal</surname>
                      <given-names>JH</given-names>
                    </name>
                  </person-group>
                  <article-title>Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics</article-title>
                  <source>Annu Rev Med</source>
                  <year>2015</year>
                  <volume>66</volume>
                  <fpage>509</fpage>
                  <lpage>23</lpage>
                  <pub-id pub-id-type="doi">10.1146/annurev-med-053013-062946</pub-id>
                  <?supplied-pmid 25341010?>
                  <pub-id pub-id-type="pmid">25341010</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Xu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Hackett</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Carter</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Loo</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>GÃ¡lvez</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Glozier</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis</article-title>
                  <source>Int J Neuropsychopharmacol</source>
                  <year>2016</year>
                  <volume>19</volume>
                  <fpage>pyv124</fpage>
                  <pub-id pub-id-type="doi">10.1093/ijnp/pyv124</pub-id>
                  <?supplied-pmid 26578082?>
                  <pub-id pub-id-type="pmid">26578082</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murrough</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Iosifescu</surname>
                      <given-names>DV</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>LC</given-names>
                    </name>
                    <name>
                      <surname>Al Jurdi</surname>
                      <given-names>RK</given-names>
                    </name>
                    <name>
                      <surname>Green</surname>
                      <given-names>CE</given-names>
                    </name>
                    <name>
                      <surname>Perez</surname>
                      <given-names>AM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial</article-title>
                  <source>Am J Psychiatry</source>
                  <year>2013</year>
                  <volume>170</volume>
                  <fpage>1134</fpage>
                  <lpage>42</lpage>
                  <pub-id pub-id-type="doi">10.1176/appi.ajp.2013.13030392</pub-id>
                  <?supplied-pmid 23982301?>
                  <pub-id pub-id-type="pmid">23982301</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McGirr</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Berlim</surname>
                      <given-names>MT</given-names>
                    </name>
                    <name>
                      <surname>Bond</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Fleck</surname>
                      <given-names>MP</given-names>
                    </name>
                    <name>
                      <surname>Yatham</surname>
                      <given-names>LN</given-names>
                    </name>
                    <name>
                      <surname>Lam</surname>
                      <given-names>RW</given-names>
                    </name>
                  </person-group>
                  <article-title>A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes</article-title>
                  <source>Psychol Med</source>
                  <year>2015</year>
                  <volume>45</volume>
                  <fpage>693</fpage>
                  <lpage>704</lpage>
                  <pub-id pub-id-type="doi">10.1017/S0033291714001603</pub-id>
                  <?supplied-pmid 25010396?>
                  <pub-id pub-id-type="pmid">25010396</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Caddy</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Giaroli</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>White</surname>
                      <given-names>TP</given-names>
                    </name>
                    <name>
                      <surname>Shergill</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Tracy</surname>
                      <given-names>DK</given-names>
                    </name>
                  </person-group>
                  <article-title>Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy</article-title>
                  <source>Ther Adv Psychopharmacol</source>
                  <year>2014</year>
                  <volume>4</volume>
                  <fpage>75</fpage>
                  <lpage>99</lpage>
                  <pub-id pub-id-type="doi">10.1177/2045125313507739</pub-id>
                  <?supplied-pmid 24688759?>
                  <pub-id pub-id-type="pmid">24688759</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Berman</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Cappiello</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Anand</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Oren</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Heninger</surname>
                      <given-names>GR</given-names>
                    </name>
                    <name>
                      <surname>Charney</surname>
                      <given-names>DS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Antidepressant effects of ketamine in depressed patients</article-title>
                  <source>Biol Psychiatry</source>
                  <year>2000</year>
                  <volume>47</volume>
                  <fpage>351</fpage>
                  <lpage>54</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0006-3223(99)00230-9</pub-id>
                  <?supplied-pmid 10686270?>
                  <pub-id pub-id-type="pmid">10686270</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Li</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>R-J</given-names>
                    </name>
                    <name>
                      <surname>Banasr</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Dwyer</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Iwata</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>MTOR-dependent synapse formation underlies the rapid antidepressant effects of nmda antagonists</article-title>
                  <source>Science.</source>
                  <year>2010</year>
                  <volume>329</volume>
                  <fpage>959</fpage>
                  <lpage>64</lpage>
                  <pub-id pub-id-type="doi">10.1126/science.1190287</pub-id>
                  <?supplied-pmid 20724638?>
                  <pub-id pub-id-type="pmid">20724638</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Duman</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Sanacora</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Krystal</surname>
                      <given-names>JH</given-names>
                    </name>
                  </person-group>
                  <article-title>Altered connectivity in depression: gaba and glutamate neurotransmitter deficits and reversal by novel treatments</article-title>
                  <source>Neuron.</source>
                  <year>2019</year>
                  <volume>102</volume>
                  <fpage>75</fpage>
                  <lpage>90</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neuron.2019.03.013</pub-id>
                  <?supplied-pmid 30946828?>
                  <pub-id pub-id-type="pmid">30946828</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murrough</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Collins</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Fields</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>DeWilde</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Phillips</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Mathew</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder</article-title>
                  <source>Transl Psychiatry</source>
                  <year>2015</year>
                  <volume>5</volume>
                  <fpage>e509</fpage>
                  <pub-id pub-id-type="doi">10.1038/tp.2015.10</pub-id>
                  <?supplied-pmid 25689570?>
                  <pub-id pub-id-type="pmid">25689570</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rivolta</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Heidegger</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Scheller</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Sauer</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Schaum</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Birkner</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ketamine dysregulates the amplitude and connectivity of high-frequency oscillations in cortical-subcortical networks in humans: evidence from resting-state magnetoencephalography-recordings</article-title>
                  <source>Schizophr Bull</source>
                  <year>2015</year>
                  <volume>41</volume>
                  <fpage>1105</fpage>
                  <lpage>14</lpage>
                  <pub-id pub-id-type="doi">10.1093/schbul/sbv051</pub-id>
                  <?supplied-pmid 25987642?>
                  <pub-id pub-id-type="pmid">25987642</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shaw</surname>
                      <given-names>AD</given-names>
                    </name>
                    <name>
                      <surname>Saxena</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>E Jackson</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Hall</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Singh</surname>
                      <given-names>KD</given-names>
                    </name>
                    <name>
                      <surname>Muthukumaraswamy</surname>
                      <given-names>SD</given-names>
                    </name>
                  </person-group>
                  <article-title>Ketamine amplifies induced gamma frequency oscillations in the human cerebral cortex</article-title>
                  <source>Eur Neuropsychopharmacol</source>
                  <year>2015</year>
                  <volume>25</volume>
                  <fpage>1136</fpage>
                  <lpage>46</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.euroneuro.2015.04.012</pub-id>
                  <?supplied-pmid 26123243?>
                  <pub-id pub-id-type="pmid">26123243</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Farmer</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Gilbert</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Moaddel</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>George</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Adeojo</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Lovett</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression</article-title>
                  <source>Neuropsychopharmacology.</source>
                  <year>2020</year>
                  <volume>45</volume>
                  <fpage>1398</fpage>
                  <lpage>404</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41386-020-0663-6</pub-id>
                  <?supplied-pmid 32252062?>
                  <pub-id pub-id-type="pmid">32252062</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nugent</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Ballard</surname>
                      <given-names>ED</given-names>
                    </name>
                    <name>
                      <surname>Gould</surname>
                      <given-names>TD</given-names>
                    </name>
                    <name>
                      <surname>Park</surname>
                      <given-names>LT</given-names>
                    </name>
                    <name>
                      <surname>Moaddel</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Brutsche</surname>
                      <given-names>NE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects</article-title>
                  <source>Mol Psychiatry</source>
                  <year>2019</year>
                  <volume>24</volume>
                  <fpage>1040</fpage>
                  <lpage>52.</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41380-018-0028-2</pub-id>
                  <?supplied-pmid 29487402?>
                  <pub-id pub-id-type="pmid">29487402</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sagi</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Tavor</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Hofstetter</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Tzur-Moryosef</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Blumenfeld-Katzir</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Assaf</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Learning in the fast lane: new insights into neuroplasticity</article-title>
                  <source>Neuron.</source>
                  <year>2012</year>
                  <volume>73</volume>
                  <fpage>1195</fpage>
                  <lpage>203</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neuron.2012.01.025</pub-id>
                  <?supplied-pmid 22445346?>
                  <pub-id pub-id-type="pmid">22445346</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tavor</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Botvinik-Nezer</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Bernstein-Eliav</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Tsarfaty</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Assaf</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Short-term plasticity following motor sequence learning revealed by diffusion magnetic resonance imaging</article-title>
                  <source>Hum Brain Mapp</source>
                  <year>2020</year>
                  <volume>41</volume>
                  <fpage>442</fpage>
                  <lpage>52.</lpage>
                  <pub-id pub-id-type="doi">10.1002/hbm.24814</pub-id>
                  <?supplied-pmid 31596547?>
                  <pub-id pub-id-type="pmid">31596547</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Just</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Keller</surname>
                      <given-names>TA</given-names>
                    </name>
                  </person-group>
                  <article-title>Converging measures of neural change at the microstructural, informational, and cortical network levels in the hippocampus during the learning of the structure of organic compounds</article-title>
                  <source>Brain Struct Funct</source>
                  <year>2019</year>
                  <volume>224</volume>
                  <fpage>1345</fpage>
                  <lpage>57.</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00429-019-01838-4</pub-id>
                  <?supplied-pmid 30725233?>
                  <pub-id pub-id-type="pmid">30725233</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Keller</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Just</surname>
                      <given-names>MA</given-names>
                    </name>
                  </person-group>
                  <article-title>Structural and functional neuroplasticity in human learning of spatial routes</article-title>
                  <source>Neuroimage.</source>
                  <year>2016</year>
                  <volume>125</volume>
                  <fpage>256</fpage>
                  <lpage>66.</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neuroimage.2015.10.015</pub-id>
                  <?supplied-pmid 26477660?>
                  <pub-id pub-id-type="pmid">26477660</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Price</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Spotts</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Panny</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Griffo</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Degutis</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Cruz</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A novel, brief, fully automated intervention extends the antidepressanteffect of a single ketamine infusion: a randomized clinical trial</article-title>
                  <source>Am J Psychiatry</source>
                  <year>2022</year>
                  <volume>179</volume>
                  <fpage>959</fpage>
                  <lpage>68</lpage>
                  <pub-id pub-id-type="doi">10.1176/appi.ajp.20220216</pub-id>
                  <?supplied-pmid 36128684?>
                  <pub-id pub-id-type="pmid">36128684</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Montgomery</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Asberg</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>A new depression scale designed to be sensitive to change</article-title>
                  <source>Br J Psychiatry</source>
                  <year>1979</year>
                  <volume>134</volume>
                  <fpage>382</fpage>
                  <lpage>89</lpage>
                  <pub-id pub-id-type="doi">10.1192/bjp.134.4.382</pub-id>
                  <?supplied-pmid 444788?>
                  <pub-id pub-id-type="pmid">444788</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chandler</surname>
                      <given-names>GM</given-names>
                    </name>
                    <name>
                      <surname>Iosifescu</surname>
                      <given-names>DV</given-names>
                    </name>
                    <name>
                      <surname>Pollack</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Targum</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Fava</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>RESEARCH: validation of the massachusetts general hospital antidepressant treatment history questionnaire (ATRQ)</article-title>
                  <source>CNS Neurosci Ther</source>
                  <year>2010</year>
                  <volume>16</volume>
                  <fpage>322</fpage>
                  <lpage>25</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1755-5949.2009.00102.x</pub-id>
                  <?supplied-pmid 19769599?>
                  <pub-id pub-id-type="pmid">19769599</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rush</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Trivedi</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Ibrahim</surname>
                      <given-names>HM</given-names>
                    </name>
                    <name>
                      <surname>Carmody</surname>
                      <given-names>TJ</given-names>
                    </name>
                    <name>
                      <surname>Arnow</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Klein</surname>
                      <given-names>DN</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression</article-title>
                  <source>Biol Psychiatry</source>
                  <year>2003</year>
                  <volume>54</volume>
                  <fpage>573</fpage>
                  <lpage>83</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0006-3223(02)01866-8</pub-id>
                  <?supplied-pmid 12946886?>
                  <pub-id pub-id-type="pmid">12946886</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Trivedi</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Rush</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Ibrahim</surname>
                      <given-names>HM</given-names>
                    </name>
                    <name>
                      <surname>Carmody</surname>
                      <given-names>TJ</given-names>
                    </name>
                    <name>
                      <surname>Biggs</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Suppes</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation</article-title>
                  <source>Psychol Med</source>
                  <year>2004</year>
                  <volume>34</volume>
                  <fpage>73</fpage>
                  <lpage>82</lpage>
                  <pub-id pub-id-type="doi">10.1017/S0033291703001107</pub-id>
                  <?supplied-pmid 14971628?>
                  <pub-id pub-id-type="pmid">14971628</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murrough</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Soleimani</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>DeWilde</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Collins</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Lapidus</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Iacoviello</surname>
                      <given-names>BM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial</article-title>
                  <source>Psychol Med</source>
                  <year>2015</year>
                  <volume>45</volume>
                  <fpage>3571</fpage>
                  <lpage>80</lpage>
                  <pub-id pub-id-type="doi">10.1017/S0033291715001506</pub-id>
                  <?supplied-pmid 26266877?>
                  <pub-id pub-id-type="pmid">26266877</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Price</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Iosifescu</surname>
                      <given-names>DV</given-names>
                    </name>
                    <name>
                      <surname>Murrough</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>LC</given-names>
                    </name>
                    <name>
                      <surname>Al Jurdi</surname>
                      <given-names>RK</given-names>
                    </name>
                    <name>
                      <surname>Iqbal</surname>
                      <given-names>SZ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression</article-title>
                  <source>Depress Anxiety</source>
                  <year>2014</year>
                  <volume>31</volume>
                  <fpage>335</fpage>
                  <lpage>43</lpage>
                  <pub-id pub-id-type="doi">10.1002/da.22253</pub-id>
                  <?supplied-pmid 24668760?>
                  <pub-id pub-id-type="pmid">24668760</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Price</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Nock</surname>
                      <given-names>MK</given-names>
                    </name>
                    <name>
                      <surname>Charney</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Mathew</surname>
                      <given-names>SJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression</article-title>
                  <source>Biol Psychiatry</source>
                  <year>2009</year>
                  <volume>66</volume>
                  <fpage>522</fpage>
                  <lpage>26</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.biopsych.2009.04.029</pub-id>
                  <?supplied-pmid 19545857?>
                  <pub-id pub-id-type="pmid">19545857</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sackeim</surname>
                      <given-names>HA</given-names>
                    </name>
                    <name>
                      <surname>Aaronson</surname>
                      <given-names>ST</given-names>
                    </name>
                    <name>
                      <surname>Bunker</surname>
                      <given-names>MT</given-names>
                    </name>
                    <name>
                      <surname>Conway</surname>
                      <given-names>CR</given-names>
                    </name>
                    <name>
                      <surname>Demitrack</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>George</surname>
                      <given-names>MS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The assessment of resistance to antidepressant treatment: rationale for the antidepressant treatment history form: short form (ATHF-SF)</article-title>
                  <source>J Psychiatr Res</source>
                  <year>2019</year>
                  <volume>113</volume>
                  <fpage>125</fpage>
                  <lpage>36.</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jpsychires.2019.03.021</pub-id>
                  <?supplied-pmid 30974339?>
                  <pub-id pub-id-type="pmid">30974339</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sackeim</surname>
                      <given-names>HA</given-names>
                    </name>
                  </person-group>
                  <article-title>The definition and meaning of treatment-resistant depression</article-title>
                  <source>J Clin Psychiatry</source>
                  <year>2001</year>
                  <volume>62</volume>
                  <fpage>10</fpage>
                  <lpage>17</lpage>
                  <?supplied-pmid 11480879?>
                  <pub-id pub-id-type="pmid">11480879</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rush</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Trivedi</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Wisniewski</surname>
                      <given-names>SR</given-names>
                    </name>
                    <name>
                      <surname>Nierenberg</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Stewart</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Warden</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a star*d report</article-title>
                  <source>Am J Psychiatry</source>
                  <year>2006</year>
                  <volume>163</volume>
                  <fpage>1905</fpage>
                  <lpage>17</lpage>
                  <pub-id pub-id-type="doi">10.1176/ajp.2006.163.11.1905</pub-id>
                  <?supplied-pmid 17074942?>
                  <pub-id pub-id-type="pmid">17074942</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Price</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Kuckertz</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Siegle</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Ladouceur</surname>
                      <given-names>CD</given-names>
                    </name>
                    <name>
                      <surname>Silk</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Ryan</surname>
                      <given-names>ND</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Empirical recommendations for improving the stability of the dot-probe task in clinical research</article-title>
                  <source>Psychol Assess</source>
                  <year>2015</year>
                  <volume>27</volume>
                  <fpage>365</fpage>
                  <lpage>76</lpage>
                  <pub-id pub-id-type="doi">10.1037/pas0000036</pub-id>
                  <?supplied-pmid 25419646?>
                  <pub-id pub-id-type="pmid">25419646</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pizzagalli</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Roberts</surname>
                      <given-names>AC</given-names>
                    </name>
                  </person-group>
                  <article-title>Prefrontal cortex and depression</article-title>
                  <source>Neuropsychopharmacology.</source>
                  <year>2022</year>
                  <volume>47</volume>
                  <fpage>225</fpage>
                  <lpage>46.</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41386-021-01101-7</pub-id>
                  <?supplied-pmid 34341498?>
                  <pub-id pub-id-type="pmid">34341498</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stuhrmann</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Suslow</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Dannlowski</surname>
                      <given-names>U</given-names>
                    </name>
                  </person-group>
                  <article-title>Facial emotion processing in major depression: a systematic review of neuroimaging findings</article-title>
                  <source>Biol Mood Anxiety Disord</source>
                  <year>2011</year>
                  <volume>1</volume>
                  <fpage>10</fpage>
                  <pub-id pub-id-type="doi">10.1186/2045-5380-1-10</pub-id>
                  <?supplied-pmid 22738433?>
                  <pub-id pub-id-type="pmid">22738433</pub-id>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ma</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis</article-title>
                  <source>Mol Psychiatry</source>
                  <year>2015</year>
                  <volume>20</volume>
                  <fpage>311</fpage>
                  <lpage>19</lpage>
                  <pub-id pub-id-type="doi">10.1038/mp.2014.24</pub-id>
                  <?supplied-pmid 24662929?>
                  <pub-id pub-id-type="pmid">24662929</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Loureiro</surname>
                      <given-names>JRA</given-names>
                    </name>
                    <name>
                      <surname>Leaver</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Vasavada</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Sahib</surname>
                      <given-names>AK</given-names>
                    </name>
                    <name>
                      <surname>Kubicki</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Joshi</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Modulation of amygdala reactivity following rapidly acting interventions for major depression</article-title>
                  <source>Hum Brain Mapp</source>
                  <year>2020</year>
                  <volume>41</volume>
                  <fpage>1699</fpage>
                  <lpage>710</lpage>
                  <pub-id pub-id-type="doi">10.1002/hbm.24895</pub-id>
                  <?supplied-pmid 32115848?>
                  <pub-id pub-id-type="pmid">32115848</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alario</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Niciu</surname>
                      <given-names>MJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Biomarkers of ketamineâs antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology</article-title>
                  <source>Chronic Stress</source>
                  <year>2021</year>
                  <volume>5</volume>
                  <fpage>24705470211014210</fpage>
                  <pub-id pub-id-type="doi">10.1177/24705470211014210</pub-id>
                  <?supplied-pmid 34159281?>
                  <pub-id pub-id-type="pmid">34159281</pub-id>
                </element-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nugent</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Farmer</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Evans</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Snider</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Banerjee</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Zarate</surname>
                      <given-names>CA</given-names>
                    </name>
                  </person-group>
                  <article-title>Multimodal imaging reveals a complex pattern of dysfunction in corticolimbic pathways in major depressive disorder</article-title>
                  <source>Hum Brain Mapp</source>
                  <year>2019</year>
                  <volume>40</volume>
                  <fpage>3940</fpage>
                  <lpage>50.</lpage>
                  <?supplied-pmid 31179620?>
                  <pub-id pub-id-type="pmid">31179620</pub-id>
                </element-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Reed</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Nugent</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Furey</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Szczepanik</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Evans</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Zarate</surname>
                      <given-names>CA</given-names>
                    </name>
                  </person-group>
                  <article-title>Ketamine normalizes brain activity during emotionally valenced attentional processing in depression</article-title>
                  <source>Neuroimage Clin</source>
                  <year>2018</year>
                  <volume>20</volume>
                  <fpage>92</fpage>
                  <lpage>101</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.nicl.2018.07.006</pub-id>
                  <?supplied-pmid 30094160?>
                  <pub-id pub-id-type="pmid">30094160</pub-id>
                </element-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Evans</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Szczepanik</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>BrutschÃ©</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Park</surname>
                      <given-names>LT</given-names>
                    </name>
                    <name>
                      <surname>Nugent</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Zarate</surname>
                      <given-names>CA</given-names>
                    </name>
                  </person-group>
                  <article-title>Default mode connectivity in major depressive disorder measured up to 10 days after ketamine administration</article-title>
                  <source>Biol Psychiatry</source>
                  <year>2018</year>
                  <volume>84</volume>
                  <fpage>582</fpage>
                  <lpage>90.</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.biopsych.2018.01.027</pub-id>
                  <?supplied-pmid 29580569?>
                  <pub-id pub-id-type="pmid">29580569</pub-id>
                </element-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nakamura</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Tomita</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Horikawa</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Ishibashi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Uematsu</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Hiraki</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment-resistant depression</article-title>
                  <source>Neuropsychopharmacol Rep.</source>
                  <year>2021</year>
                  <volume>41</volume>
                  <fpage>168</fpage>
                  <lpage>78.</lpage>
                  <pub-id pub-id-type="doi">10.1002/npr2.12165</pub-id>
                  <?supplied-pmid 33615749?>
                  <pub-id pub-id-type="pmid">33615749</pub-id>
                </element-citation>
              </ref>
              <ref id="CR55">
                <label>55.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rivas-Grajales</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Salas</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Robinson</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Qi</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Murrough</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Mathew</surname>
                      <given-names>SJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Habenula connectivity and intravenous ketamine in treatment-resistant depression</article-title>
                  <source>Int J Neuropsychopharmacol</source>
                  <year>2021</year>
                  <volume>24</volume>
                  <fpage>383</fpage>
                  <lpage>91.</lpage>
                  <pub-id pub-id-type="doi">10.1093/ijnp/pyaa089</pub-id>
                  <?supplied-pmid 33249434?>
                  <pub-id pub-id-type="pmid">33249434</pub-id>
                </element-citation>
              </ref>
              <ref id="CR56">
                <label>56.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>M-H</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>W-C</given-names>
                    </name>
                    <name>
                      <surname>Tu</surname>
                      <given-names>P-C</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>C-T</given-names>
                    </name>
                    <name>
                      <surname>Bai</surname>
                      <given-names>Y-M</given-names>
                    </name>
                    <name>
                      <surname>Tsai</surname>
                      <given-names>S-J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: a double-blind, placebo-controlled, randomized, longitudinal resting fMRI study</article-title>
                  <source>J Affect Disord</source>
                  <year>2019</year>
                  <volume>259</volume>
                  <fpage>15</fpage>
                  <lpage>20</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jad.2019.08.022</pub-id>
                  <?supplied-pmid 31437695?>
                  <pub-id pub-id-type="pmid">31437695</pub-id>
                </element-citation>
              </ref>
              <ref id="CR57">
                <label>57.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Takeuchi</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Taki</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Nouchi</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Yokoyama</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Kotozaki</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Nakagawa</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Empathizing associates with mean diffusivity</article-title>
                  <source>Sci Rep.</source>
                  <year>2019</year>
                  <volume>9</volume>
                  <fpage>8856</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41598-019-45106-1</pub-id>
                  <?supplied-pmid 31222093?>
                  <pub-id pub-id-type="pmid">31222093</pub-id>
                </element-citation>
              </ref>
              <ref id="CR58">
                <label>58.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Takeuchi</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Taki</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Nouchi</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Hashizume</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Sekiguchi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kotozaki</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Working memory training impacts the mean diffusivity in the dopaminergic system</article-title>
                  <source>Brain Struct Funct</source>
                  <year>2015</year>
                  <volume>220</volume>
                  <fpage>3101</fpage>
                  <lpage>11</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00429-014-0845-2</pub-id>
                  <?supplied-pmid 25023736?>
                  <pub-id pub-id-type="pmid">25023736</pub-id>
                </element-citation>
              </ref>
              <ref id="CR59">
                <label>59.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Song</surname>
                      <given-names>AW</given-names>
                    </name>
                    <name>
                      <surname>Woldorff</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>Gangstead</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Mangun</surname>
                      <given-names>GR</given-names>
                    </name>
                    <name>
                      <surname>McCarthy</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Enhanced spatial localization of neuronal activation using simultaneous apparent-diffusion-coefficient and blood-oxygenation functional magnetic resonance imaging</article-title>
                  <source>Neuroimage.</source>
                  <year>2002</year>
                  <volume>17</volume>
                  <fpage>742</fpage>
                  <lpage>50</lpage>
                  <pub-id pub-id-type="doi">10.1006/nimg.2002.1217</pub-id>
                  <?supplied-pmid 12377149?>
                  <pub-id pub-id-type="pmid">12377149</pub-id>
                </element-citation>
              </ref>
              <ref id="CR60">
                <label>60.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jin</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>S-G</given-names>
                    </name>
                  </person-group>
                  <article-title>Functional changes of apparent diffusion coefficient during visual stimulation investigated by diffusion-weighted gradient-echo fMRI</article-title>
                  <source>Neuroimage.</source>
                  <year>2008</year>
                  <volume>41</volume>
                  <fpage>801</fpage>
                  <lpage>12</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neuroimage.2008.03.014</pub-id>
                  <?supplied-pmid 18450483?>
                  <pub-id pub-id-type="pmid">18450483</pub-id>
                </element-citation>
              </ref>
              <ref id="CR61">
                <label>61.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Xu</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Zhong</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Iron deposition influences the measurement of water diffusion tensor in the human brain: a combined analysis of diffusion and iron-induced phase changes</article-title>
                  <source>Neuroradiology.</source>
                  <year>2015</year>
                  <volume>57</volume>
                  <fpage>1169</fpage>
                  <lpage>78</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00234-015-1579-4</pub-id>
                  <?supplied-pmid 26307228?>
                  <pub-id pub-id-type="pmid">26307228</pub-id>
                </element-citation>
              </ref>
              <ref id="CR62">
                <label>62.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Taraku</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Woods</surname>
                      <given-names>RP</given-names>
                    </name>
                    <name>
                      <surname>Boucher</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Espinoza</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Jog</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Al-Sharif</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Changes in white matter microstructure following serial ketamine infusions in treatment resistant depression</article-title>
                  <source>Hum Brain Mapp</source>
                  <year>2023</year>
                  <volume>44</volume>
                  <fpage>2395</fpage>
                  <lpage>406</lpage>
                  <pub-id pub-id-type="doi">10.1002/hbm.26217</pub-id>
                  <?supplied-pmid 36715291?>
                  <pub-id pub-id-type="pmid">36715291</pub-id>
                </element-citation>
              </ref>
              <ref id="CR63">
                <label>63.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sydnor</surname>
                      <given-names>VJ</given-names>
                    </name>
                    <name>
                      <surname>Lyall</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>Cetin-Karayumak</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Cheung</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Felicione</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Akeju</surname>
                      <given-names>O</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamineâs antidepressant effects</article-title>
                  <source>Transl Psychiatry</source>
                  <year>2020</year>
                  <volume>10</volume>
                  <fpage>432</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41398-020-01122-8</pub-id>
                  <?supplied-pmid 33319774?>
                  <pub-id pub-id-type="pmid">33319774</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
